|
|
Article: Phase II Study of SuperGen's Pentostatin (Nipent(R)), in Combination with Rituximab, Showed 71% Overall Response Rate Among Patients with Low-Grade Non-Hodgkin's Lymphoma (NHL), and 'Remarkably Little Toxicity'.
- Article from:
- PR Newswire
- Article date:
- November 8, 2001
CopyrightCOPYRIGHT 2001 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Data presented at "Innovative Cancer Therapy for Tomorrow" symposium sponsored
by Mount Sinai School of Medicine and Chemotherapy Foundation
DUBLIN, Calif., Nov. 8 /PRNewswire/ --
SuperGen Inc. (Nasdaq: SUPG) announced today that data from an ongoing phase II study of its anticancer compound pentostatin (Nipent(R)) in combination with rituximab showed the regimen was "remarkably well-tolerated in patients with indolent (low-grade) non-Hodgkin's disease," said Robert L. Drapkin, M.D., of U.S. Oncology South West Florida.
Dr. Drapkin presented his clinical data to colleagues attending this week's "19th Annual Symposium on Innovative ...